Hypertensive disorders of pregnancy and risk of cardiovascular disease: A Mendelian Randomisation study in the UK Biobank

Lena Tschiderer, PhD,^{1,2} Yvonne T van der Schouw, PhD,² Stephen Burgess, PhD,^{3,4,5} Kitty WM Bloemenkamp, PhD,⁶ Lisa Seekircher, PhD,¹ Peter Willeit, PhD,^{1,3} N Charlotte Onland-Moret, PhD,² Sanne AE Peters, PhD^{2,7,8}

¹Institute of Health Economics, Medical University of Innsbruck, Innsbruck, Austria; ²Julius Centre for Health Sciences and Primary Care, University Medical Centre Utrecht, Utrecht, the Netherlands; ³Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; ⁴Heart and Lung Research Institute, University of Cambridge, Cambridge, United Kingdom; ⁵MRC Biostatistics Unit, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom; ⁶Department of Obstetrics, Division Women and Baby, Birth Centre Wilhelmina Children Hospital, University Medical Centre Utrecht, Utrecht, the Netherlands; ⁷The George Institute for Global Health, School of Public Health, Imperial College London, London, United Kingdom; ⁸The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia.

Short title: Hypertensive disorders of pregnancy & CVD risk

Correspondence to:

Sanne AE Peters

Julius Centre for Health Sciences and Primary Care, University Medical Centre

Utrecht, Utrecht, the Netherlands

Phone: +31887568181

E-mail: S.A.E.Peters@umcutrecht.nl

Word count: 5,992; 1 Table; 4 Figures

Abstract

1

5

8

10

11

20

21

24

25

2 **Background:** Observational studies show that hypertensive disorders of pregnancy

3 (HDPs) are related to unfavourable maternal cardiovascular disease (CVD) risk

4 profiles later in life. We investigated whether genetic liability to pre-

eclampsia/eclampsia and gestational hypertension is associated with CVD risk

6 factors and occurrence of CVD events.

7 **Methods:** We obtained genetic associations with HDPs from a genome-wide

association study and used individual-participant-data of women and men from the

9 UK Biobank to obtain genetic associations with CVD risk factors and CVD events

(defined as myocardial infarction or stroke). The rationale for including men and

nulligravidae was to study genetic liability to HDPs and CVD risk without

12 experiencing the underlying phenotype. We applied Mendelian Randomisation

analysis using inverse variance weighted regression in our primary analysis.

14 **Results:** We included 264,160 women (mean age 56.4 [SD 8.0]) and 223,043 men

15 (mean age 56.7 [8.2]) with available genetic data. Genetically proxied pre-

eclampsia/eclampsia was related to higher risk of CVD with odds ratios of 1.20 (1.01,

17 1.43) and 1.29 (1.08, 1.53) in women and men, respectively. For genetically proxied

18 gestational hypertension, odds ratios for CVD were 1.22 (1.10, 1.36) and 1.28 (1.16,

19 1.42) in women and men, respectively. Furthermore, genetically proxied HDPs were

associated with higher levels of systolic and diastolic blood pressure and younger

age at hypertension diagnosis in both women and men.

22 Conclusions: Genetic liability to HDPs including pre-eclampsia/eclampsia and

23 gestational hypertension is associated with higher CVD risk, implying biological

mechanisms relating to these disorders are causally related to CVD risk in both

women and men.

Introduction

26

27

28

29

30 31

32

33 34

35

36

37

38 39

40

41 42

43 44

45

46 47

48

49

50 51

52

53

54

55

56

Hypertensive disorders of pregnancy (HDPs) affected one in eight hospital deliveries in 2019 and came along with one in four maternal deaths between 2017 and 2019 in the US. Globally, there were 18.1 million incident cases of hypertensive pregnancy disorders in 2019.² They can express as different phenotypes including gestational hypertension, pre-eclampsia/eclampsia, and HELLP syndrome. Pre-eclampsia is a multi-organ disease originating from a dysfunction of the placenta and affects approximately one in twenty deliveries. 3,4 The International Society for the Study of Hypertension in Pregnancy defines pre-eclampsia as gestational hypertension with one or more of the following concomitants: (1) proteinuria, (2) other maternal organ dysfunction (acute kidney injury, liver involvement, neurological or haematological complications), or (3) uteroplacental dysfunction.⁵ Eclampsia is a progression of preeclampsia, in which women additionally experience seizures. 6 Gestational hypertension is defined as *de novo* hypertension at ≥20 weeks of gestation without the additional signs of pre-eclampsia.⁵ A range of risk factors for HDPs have been proposed including higher pre-pregnancy body mass index (BMI), pre-pregnancy diabetes mellitus, chronic hypertension, chronic autoimmune disease, and maternal age. 7,8 Furthermore, HDPs are related to multiple immediate, short-term, and long-term health concerns, which can affect the mother and the foetus and neonate. Short-term outcomes are, for instance, stillbirth and preterm delivery, whereas on the long term HDPs are associated with maternal risk factors cardiovascular after pregnancy including diabetes hyperlipidaemia, and hypertension.9 Observational studies have also reported a relation between HDPs and higher risk of maternal cardiovascular disease (CVD) events later in life,9 which has been confirmed in co-sibling analyses10 and by a previous Mendelian Randomisation (MR) study that was restricted to sex-combined genetic associations with CVD events. 11 However, the specific biological mechanisms behind HDPs and CVD risk are not entirely clear. As HDPs and CVD share a considerable amount of risk factors, the theory emerged that both phenotypes are expressions of the same disease pathway at different stages in life, 12 and that pregnancy enables earlier identification of

- 57 women at higher CVD risk. 13 Apart from that, HDPs could also cause long-term
- vascular damage leading to a higher CVD risk later in life. 13
- 59 To better understand the role of HDPs in the development of CVD, we conducted a
- 60 MR analysis of 487,203 women and men from the UK Biobank with the aim to
- 61 estimate the sex-specific relation of genetic liability to pre-eclampsia/eclampsia and
- 62 gestational hypertension with CVD events, blood pressure-traits, and lipid-, liver-,
- and kidney-related cardiovascular risk factors. The rationale for also analysing men
- and nulligravidae was to study the role of genetic liability to HDPs in cardiovascular
- 65 risk without experiencing the underlying phenotype, which could help understand
- 66 whether biological mechanisms related to HDPs or the diseases themselves are
- 67 responsible for higher CVD risk.

Methods

68

71

- This analysis adheres to the STROBE-MR statement (**Table S1**). 14 Please see the
- 70 Major Resources Table in the Supplemental Materials.

Study design and data sources

- 72 The present study included data from the UK Biobank, of which details have been
- described previously. 15 Briefly, the UK Biobank is a large-scale prospective study in
- the general population of the UK, in which over 500,000 individuals aged 40 to 69
- 75 years were recruited between 2006 and 2010. The UK Biobank was approved by
- 76 the North-West Multi-Centre Research Ethics Committee and all participants
- 77 provided written informed consent.
- 78 For the MR analysis, we used individual-level imputed data on genetic variants.
- 79 Genotyping was performed using the Affymetrix UK BiLEVE Axiom array and the
- 80 Affymetrix UK Biobank Axiom Array. 16,17 Genotype imputation was based on the
- Haplotype Reference Consortium and the UK10K haplotype reference panel. 18
- 82 Of the 502,412 UK Biobank participants, we excluded 15,209 individuals because
- 83 they had missing values on the genetic variants included in our analysis. The
- remaining 487,203 individuals contributed to the present analysis.

- 85 Specific definitions of pre-eclampsia/eclampsia, gestational hypertension, CVD
- 86 events, and additional variables are outlined in **Supplementary Methods**.

Statistical analysis

- 88 We summarised continuous variables with mean and standard deviation (SD), if
- 89 normally distributed, and with median and interquartile range, otherwise. Categorical
- 90 variables were summarised with number and percentage. For all analyses, we used
- 91 two-sided statistical tests and deemed P-values≤0.05 as statistically significant.
- 92 Analyses were carried out using R 4.0.5 (The R Foundation, Vienna, Austria).

Instrumental variable

- 94 For our instrumental variables, we used SNPs for pre-eclampsia/eclampsia and
- 95 gestational hypertension identified by a recent genome-wide association study
- 96 (GWAS) by Honigberg et al. 19 We used effect sizes and standard errors from the
- 97 discovery analysis, which excluded data from the UK Biobank, allowing two-sample
- 98 MR.¹⁹

87

93

- 99 As illustrated in Figure S1, twelve SNPs for pre-eclampsia/eclampsia and seven
- 100 SNPs for gestational hypertension were identified by the GWAS.¹⁹ We harmonised
- 101 the summary-level data to be represented on the same strand. Furthermore, we
- 102 excluded palindromic SNPs with allele frequencies between 0.45 and 0.55. For both
- exposures, we excluded one palindromic SNP (rs9855086). To identify related traits,
- 104 we scanned Phenoscanner²⁰ (on February 14th 2023) and extracted all traits
- 105 associated with the SNPs or any proxies in high linkage disequilibrium (R²≥0.8) with
- 106 P-values≤5×10⁻⁸ omitting traits identified from the UK Biobank by Neale et al.
- 107 (http://www.nealelab.is/uk-biobank/). Details on the SNPs included in the present
- analysis and related traits are provided in **Table S2**.
- 109 We measured the strength of our instrumental variable based on the F-statistics of
- each SNP individually, which ranged from 30 to 58.

111 Primary analysis

- We conducted all analyses sex-specific and for women and men combined. For the
- association between the genetic variants and CVD events, we implemented logistic
- 114 regression adjusting for age at baseline, sex, if appropriate, and the first 16 genetic
- principal components, as suggested previously.²¹ We conducted the MR analysis

using the R-package *MendelianRandomization*.²² In the primary analysis, we applied inverse variance weighted (IVW) regression. We obtained women-to-men ratios of odds ratios (ORs) and 95% confidence intervals (CIs) by subtracting logORs for men from logORs for women and adding sex-specific variances. All ORs in MR analyses are reported per unit increase in the log odds of genetically proxied pre-eclampsia/eclampsia and gestational hypertension.

Sensitivity analyses

116117

118

119

120

121

122

135

- 123 Sensitivity analyses were conducted similarly to the primary analysis but by applying
- simple and weighted median regression, MR-Egger, and MR-PRESSO.²³
- 125 Furthermore, we studied associations between genetic variants and CVD events
- 126 using a Cox proportional hazards model. We used age as underlying timescale and
- adjusted for sex, if appropriate, and the first 16 genetic principal components. For
- this sensitivity analysis we excluded all individuals with history of CVD (defined as
- myocardial infarction or stroke) at baseline. Time-to-event was defined as time to the
- first CVD event, death, or end of follow-up, whichever occurred first.
- 131 Moreover, we conducted a sensitivity analysis, classifying women into ever and
- never pregnant. We obtained ever-to-never-pregnant ratios of ORs and 95% Cls by
- 133 subtracting logORs for never pregnant from logORs for ever pregnant women and
- 134 adding corresponding variances.

Secondary analyses

- 136 In addition, we conducted a MR analysis using a set of cardiovascular risk factors as
- 137 outcome variables. We analysed blood pressure-related traits including systolic
- 138 blood pressure (SBP), diastolic blood pressure (DBP), and age at hypertension
- diagnosis. Furthermore, we analysed additional CVD risk factors including BMI, total
- 140 cholesterol, high-density lipoprotein cholesterol, triglycerides, low-density lipoprotein
- 141 cholesterol, lipoprotein(a), apolipoprotein A1, apolipoprotein B, HbA1c, creatinine,
- 142 albumin, ALAT, ASAT, GGT, and C-reactive protein. For obtaining genetic
- associations with risk factors, we used linear regression analysis adjusting for age,
- sex, if appropriate, and the first 16 genetic principal components, ²¹ and divided all
- 145 cardiovascular risk factors by their SD to enhance the comparison between the
- individual risk factors. The MR analysis was based on IVW regression.

Results

147

148

154

Characteristics of the study population

- 149 Baseline characteristics of the included participants are outlined in **Table 1**. The
- 150 present analysis included 264,160 (54%) women and 223,043 (46%) men. Mean age
- at baseline was 56.5 (SD 8.1) years. CVD was reported in 13,861 women (7,232
- 152 myocardial infarctions; 7,436 strokes) and 27,682 men (19,746 myocardial
- infarctions; 10,104 strokes).

MR analysis of genetically proxied HDPs and risk of CVD

155 **Primary analysis**

- 156 As depicted in Figure 1, in women and men, respectively, genetically proxied pre-
- eclampsia/eclampsia was related to a higher risk of CVD with ORs of 1.20 (95% CI
- 158 1.01, 1.43) and 1.29 (1.08, 1.53) and to a higher risk of ischaemic CVD with ORs of
- 1.59 1.24 (1.02, 1.52) and 1.32 (1.10, 1.59). We found no significant association with risk
- 160 of haemorrhagic stroke. Women-to-men ratios of ORs revealed no differences
- 161 between sexes.
- 162 **Figure 2** shows the MR analyses for gestational hypertension and CVD events. In
- 163 women and men, respectively, ORs were 1.22 (1.10, 1.36) and 1.28 (1.16, 1.42) for
- 164 CVD and 1.22 (1.10, 1.37) and 1.32 (1.19, 1.47) for ischaemic CVD. ORs for
- 165 haemorrhagic stroke were 1.37 (1.07, 1.77) and 1.12 (0.72, 1.75) in women and
- 166 men, respectively. Again, women-to-men ratios of ORs were not statistically
- significantly different from one.
- 168 In sex-combined analyses both genetically proxied HDPs were related to a higher
- risk of CVD, ischaemic CVD, myocardial infarction, stroke, and ischaemic stroke, but
- 170 not with haemorrhagic stroke and intracerebral haemorrhage (Figure S2 and Figure
- 171 **\$3**). Genetically proxied gestational hypertension but not pre-eclampsia/eclampsia
- was associated with higher risk of subarachnoid haemorrhage.

173 **Sensitivity analyses**

- 174 In sensitivity analyses, applying simple and weighted median regression, results
- were broadly similar when investigating genetically proxied pre-eclampsia/eclampsia
- in women (Figure S4), men (Figure S5), and women and men combined (Figure

177

178

179

180

181

182

183

184

185

186

187

188

189

190191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

S6). When applying MR-Egger, the OR for intracerebral haemorrhage was 6.21 (1.16, 33.31) in the sex-combined analysis with indication of directional pleiotropy (Pvalue intercept=0.027). ORs from MR-Egger regression for all other cardiovascular events were not statistically significant. **Table S3** shows the results of MR-PRESSO, which detected outlying variants in the analysis of women, men, and in the sexcombined analysis. The effect sizes remained similar but the association between genetically proxied pre-eclampsia/eclampsia and higher risk of myocardial infarction in women became statistically significant. When analysing genetically proxied gestational hypertension, results remained robust when implementing simple or median weighted regression for the analysis in women (Figure S7), in men (Figure S8), and in sex-combined analyses (Figure S9). In women, MR-Egger regression yielded a statistically significant intercept (Pvalue=0.002) when analysing the combined stroke endpoint (Figure S7). Table S3 shows the results of MR-PRESSO, in which genetically proxied gestational hypertension was statistically significantly related to a higher risk of haemorrhagic stroke in the sex-combined analysis (OR 1.32 [1.22, 1.44]). The Cox regression analysis included 258,416 women and 209,387 men without a history of CVD at baseline. As depicted in Figure S10, results remained broadly similar compared the primary analysis. Genetically proxied to eclampsia/eclampsia was related to hazard ratios of 1.13 (0.95, 1.34) and 1.20 (1.01, 1.44) for CVD in women and men, respectively, with no significant differences between the sexes. Hazard ratios for CVD were 1.17 (1.03, 1.32) in women and 1.25 (1.13, 1.38) in men, when analysing genetically proxied gestational hypertension (Figure S11). Results of the sex-combined analysis are provided in Figure S12 and **Figure S13** and were also comparable to the findings of the primary analysis. Figure S14 and Figure S15 show the MR analyses by history of pregnancy. The excess risk for ischaemic stroke for genetic liability to gestational hypertension was higher in ever compared to never pregnant women with a ratio of ORs of 1.84 (1.04, 3.24). We found no significant differences when analysing pre-eclampsia/eclampsia and gestational hypertension and other CVD events.

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

MR analysis of genetically proxied HDPs with blood pressure-traits and cardiovascular risk factors Figure 3 shows the associations genetically between proxied eclampsia/eclampsia and a range of cardiovascular risk factors. Genetically proxied pre-eclampsia/eclampsia was related to higher levels of SBP and DBP and younger age at hypertension diagnosis. Furthermore, we found a significant association with lower levels of total cholesterol in both women and men. There were no sexdifferences in any of the associations. Relations between genetically proxied gestational hypertension and cardiovascular risk factors are depicted in Figure 4. Genetically proxied gestational hypertension was associated with higher levels of SBP and DBP and younger age at hypertension diagnosis in women and men with no statistically significant differences between women and men. Sex-combined analyses for genetically proxied pre-eclampsia/eclampsia and gestational hypertension are shown in Figure S16 and Figure S17, respectively. genetically proxied pre-eclampsia/eclampsia and hypertension were related to higher levels of SBP and DBP and younger age at hypertension diagnosis. Additionally, genetically proxied pre-eclampsia/eclampsia was associated with lower levels of several lipid parameters. **Discussion** In this analysis, we found associations between genetic liability to preeclampsia/eclampsia and gestational hypertension and higher risk of CVD in both women and men. Furthermore, both HDPs were related to higher levels of SBP and DBP and younger age at hypertension diagnosis. Findings from previous studies A positive association between HDPs and risk of CVD has previously been reported by observational studies. A large-scale meta-analysis showed that moderate and severe pre-eclampsia are associated with a higher risk of maternal CVD, with ORs of 2.24 (1.72, 2.93) and 2.74 (2.48, 3.04), respectively.²⁴ The same is the case for gestational hypertension, for which an OR for maternal CVD of 1.67 (1.28, 2.19) has been reported.²⁴ Moreover, a phenome-wide association analysis showed strong associations between polygenic risk scores of HDPs with CVD risk factors (such as hypertension, diabetes mellitus, hyperlipidaemia, and obesity) and CVD events (including ischaemic heart disease and coronary atherosclerosis) in women and men. 19 In addition, a recent MR analysis, which only included women for genetic associations with HDPs, showed genetically proxied HDPs to be related to a higher risk of coronary artery disease or ischaemic stroke. 11 Furthermore, genetically proxied pre-eclampsia and gestational hypertension were associated with a higher risk of coronary artery disease but not with risk of ischaemic stroke. 11 This is not in line with the results of the present study, in which we did find a significantly higher risk for ischaemic stroke for genetically proxied pre-eclampsia/eclampsia in women. However, it has to be noted that the previous MR study only included data from one database for obtaining genetic associations with genetically proxied HDPs and used sex-combined effect sizes for the genetic associations with CVD events, which could potentially explain these differences. 11 In the present MR study, we (1) used effect sizes for the genetic association with the exposure from a large-scale GWAS that meta-analysed results of multiple studies, (2) analysed sex-specific effect sizes for the genetic association with the outcome, (3) included analyses restricted to men, and (4) studied associations with blood pressure-, lipid-, liver-, and kidney-related traits.

HDPs and blood pressure

236

237238

239

240

241

242

243244

245

246

247

248

249

250

251252

253

254

255

256

257

258

259

260

261

262

263264

265266

267

268

Per definition, hypertension is the major component of HDPs. In the present analysis, we showed that genetically proxied pre-eclampsia/eclampsia and gestational hypertension are significantly associated with both higher SBP and DBP later in life. Genetic correlation between HDPs and blood pressure has previously been demonstrated. Notably, the genetic correlation between gestational hypertension and SBP was even higher than between SBP and DBP. A previous MR analysis showed that higher genetically predicted SBP was also related to an elevated risk for pre-eclampsia/eclampsia. Moreover, higher levels of genetically proxied blood pressure have been related to an increased risk of CVD in both women and men. In case blood pressure lies on the causal pathway between pre-eclampsia/eclampsia and gestational hypertension and CVD, we speak of vertical

pleiotropy, which does not bias the findings of our MR analysis. However, we cannot fully exclude horizontal pleiotropy, which would violate the assumptions of MR. When applying MR-Egger, we found no significant intercepts in the relation of preeclampsia/eclampsia and CVD, which indicates absence of directional pleiotropy. We did find a significant MR-Egger intercept in the association between genetically proxied gestational hypertension and risk of stroke and ischaemic stroke in women. However, it has previously been discussed that MR-Egger results can be influenced by outlying variants.²⁷ When we further studied the relation between genetically proxied gestational hypertension and risk of stroke and ischaemic stroke applying MR-PRESSO, the findings of our primary analysis remained robust.

Differences between ischaemic and haemorrhagic events

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287288

289

290

291

292

293

294

295

296

297

298

299

300

301

MR analysis revealed both pre-eclampsia/eclampsia and gestational Our hypertension to be related to ischaemic CVD. Contrarily, we found no statistically significant association between pre-eclampsia/eclampsia and risk of haemorrhagic stroke. These findings are not in line with results from previous observational studies. In a US database it has been shown that pre-eclampsia/eclampsia was associated with an OR for pregnancy-related intracerebral haemorrhage of 10.39 (8.32, 12.98).²⁸ Moreover, a study from Taiwan reported a hazard ratio for haemorrhagic stroke of 3.50 (2.31, 5.29) related to pre-eclampsia.²⁹ Another analysis in Canadian women found pre-eclampsia to be related to a higher risk of haemorrhagic stroke. 30 Therefore, our findings suggest that the results of observational studies may be biased by potential confounding factors affecting the relation between pre-eclampsia/eclampsia and risk of haemorrhagic stroke. However, especially our sex-specific analysis may have limited statistical power to analyse haemorrhagic stroke events, which could have prevented us from finding statistically significant associations. Nevertheless, in sex-combined analyses, we did also not find significant association of genetically proxied eclampsia/eclampsia and occurrence of haemorrhagic stroke. In contrast, we did find a statistically significant association between genetically proxied gestational hypertension and the risk of subarachnoid haemorrhage in our sex-combined analysis. This indicates potential differences between the roles of preeclampsia/eclampsia and gestational hypertension in the risk for haemorrhagic stroke.

HDPs in men and nulligravidae

302

303

304

305

306

307

308

309310

311

312

313

314

315

316317

318

319

320

321

322

323

324

325

326

327

328

329330

331

332

333

Our MR analysis also included men and nulligravidae, who can have the genetic liability to HDPs although the underlying phenotype can never express. Nevertheless, we found genetic liability to pre-eclampsia/eclampsia and gestational hypertension to be related to a higher risk of CVD events in men. Robillard et al. previously suggested the importance paternity in the development of pre-eclampsia and reported a significantly higher risk for pre-eclampsia in new paternity multiparas compared to same paternity multiparas and primiparas.³¹ To further investigate how the genetic liability to HDPs expresses in men, we studied their relationship with a range of cardiovascular risk factors. Interestingly, genetically proxied HDPs were also related to younger age at hypertension diagnosis in men. A recently conducted phenome-wide association study investigated the relation between polygenic risk scores for pre-eclampsia/eclampsia and gestational hypertension with >1,000 phenotypes in men and also reported hypertension to be one of the key associated characteristics. 19 This is indicative that earlier hypertension is a main driver of the underlying mechanisms leading to a higher CVD risk in males. We also analysed the genetic liability to HDPs and CVD in nulligravidae. Relations were similar in never and ever pregnant women for all CVD events, but ischaemic stroke, as we found a statistically significantly higher excess risk for ischaemic stroke related to the genetic liability to gestational hypertension for ever compared to never pregnant women. However, it should be noted that statistical power for the analysis of nulligravid women was limited. Consequently, the role of genetic liability to HDPs in CVD risk in nulligravidae needs further investigation.

Strengths and limitations

Our study has several strengths. We used data from UK Biobank, which provided adequate statistical power to conduct the MR analyses. Furthermore, we built our genetic instruments on a comprehensive large-scale GWAS that meta-analysed data from multiple studies. ¹⁹ Moreover, due to the use of individual-participant data from the UK Biobank, we were able to study sex-specific associations of genetic variants with CVD events. In addition, we conducted several sensitivity analyses including different methods of MR and a Cox-regression analysis based on time-to-event data. Our analysis also has limitations. First, the effect sizes for the genetic association

with the exposure variable were based on individuals of different ancestries, while the UK Biobank majorly includes individuals of European ancestry. Furthermore, we did not have adequate statistical power for analysing nulligravid women, limiting the interpretation of our findings. Moreover, MR analysis relies on three assumptions. The first assumption is that the instrumental variable is associated with the exposure. Phenotypic data on pre-eclampsia/eclampsia and gestational hypertension were not available in our dataset. Consequently, we were not able to investigate whether the genetic instruments correlated with the phenotype in our study. However, we calculated F-statistics for each SNP individually and all of them were ≥30 indicating that we have sufficiently strong instruments. In addition, these SNPs were obtained from an independent GWAS, which replicated the majority of associations in additional cohorts, supporting our assumption of having robust associations with the exposures. The second assumption is that the genetic instrument is not associated to any confounding factor. We studied the association of genetically proxied preeclampsia/eclampsia and gestational hypertension with several cardiovascular risk factors. We found significant associations between genetically predicted HDPs and lower levels of lipid parameters. As lower levels of some lipid parameters (e.g., total cholesterol) are known to be related to a lower cardiovascular risk, 32 while others have been related to a higher cardiovascular risk (e.g., high-density lipoprotein cholesterol),³³ the specific role of lipid levels on the pathway between HDPs and risk of cardiovascular events needs to be further investigated. The third assumption is that the genetic instrument can influence the outcome only via the exposure. To study this assumption, we conducted MR-Egger regression and MR-PRESSO, which indicated potential directional pleiotropy for single CVD events as discussed in detail above.

Conclusion

334

335

336

337

338

339

340

341

342

343

344345

346

347

348

349

350

351

352

353 354

355

356

357

358

359

360

361

362

Genetic liability to HDPs including pre-eclampsia/eclampsia and gestational hypertension is associated with higher CVD risk, implying biological mechanisms relating to these disorders are causally related to CVD risk in both women and men.

Perspectives

363

364

365

366

367

368

369

370

371

372

373

374

375

376

378

382

This MR study demonstrated that genetic liability to pre-eclampsia/eclampsia and gestational hypertension is related to a higher risk for CVD. Additionally, genetic liability to HDPs was related to higher blood pressure levels and younger age at hypertension diagnosis. The findings were similar in women and men. This implies that biological mechanisms related to HDPs are causally related to CVD risk. Furthermore, it suggests that both HDPs and CVD events may be expressions of the same disease pathway at different stages in life and that HDPs may be an indicator for individuals at higher CVD risk later in life. While pregnancy allows identification of women at increased risk for future CVD, men and nulligravidae with the same genetic liability to HDPs may not have the opportunity to present at an earlier stage in life.

Acknowledgements

- This research has been conducted using the UK Biobank Resource (Application
- Number 29916). We are extremely grateful to all participants in the UK Biobank.

Sources of Funding

- 379 This work was funded by the Austrian Science Fund (T 1253). SAEP is supported by
- 380 a VIDI Fellowship from the Dutch Organisation for Health Research and
- 381 Development (ZonMw) (09150172010050).

Disclosures

383 None.

Data availability

Summary-level data from the GWAS have been published previously. Data from the UK Biobank can be requested via their website (https://www.ukbiobank.ac.uk/enable-your-research/apply-for-access).

Novelty and Relevance

What is New?

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

 This Mendelian Randomisation study investigated the relation between genetically predicted hypertensive disorders of pregnancy and the risk of developing cardiovascular disease and several cardiovascular risk factors.

What is Relevant?

- The study found genetic liability to pre-eclampsia/eclampsia and gestational hypertension to be linked to a higher risk of cardiovascular disease events in both women and men.
- Earlier hypertension appears to be a main driver behind the relation of hypertensive disorders of pregnancy and increased cardiovascular risk.

Clinical/Pathophysiological implications?

 Hypertensive disorders of pregnancy seem to be an indicator for individuals at higher cardiovascular disease risk later in life.

References

403

- 404 1. Ford ND, Cox S, Ko JY, Ouyang L, Romero L, Colarusso T, Ferre CD,
- 405 Kroelinger CD, Hayes DK, Barfield WD. Hypertensive Disorders in Pregnancy
- 406 and Mortality at Delivery Hospitalization United States, 2017-2019. MMWR
- 407 *Morb Mortal Wkly Rep.* 2022;71:585–591. doi: 10.15585/mmwr.mm7117a1.
- 408 2. Global burden of 369 diseases and injuries in 204 countries and territories,
- 409 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
- 410 Lancet. 2020;396:1204–1222. doi: 10.1016/S0140-6736(20)30925-9.
- 411 3. Abalos E, Cuesta C, Grosso AL, Chou D, Say L. Global and regional estimates
- of preeclampsia and eclampsia: a systematic review. Eur J Obstet Gynecol
- 413 Reprod Biol. 2013;170:1–7. doi: 10.1016/j.ejogrb.2013.05.005.
- 414 4. Chappell LC, Cluver CA, Kingdom J, Tong S. Pre-eclampsia. *Lancet*.
- 415 2021;398:341–354. doi: 10.1016/S0140-6736(20)32335-7.
- 416 5. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S, Hall
- DR, Warren CE, Adoyi G, Ishaku S. Hypertensive Disorders of Pregnancy:
- 418 ISSHP Classification, Diagnosis, and Management Recommendations for
- International Practice. *Hypertension*. 2018;72:24–43. doi:
- 420 10.1161/HYPERTENSIONAHA.117.10803.
- 421 6. National High Blood Pressure Education Program Working Group on High Blood
- 422 Pressure. Report of the National High Blood Pressure Education Program
- Working Group on High Blood Pressure in Pregnancy. American Journal of
- 424 Obstetrics and Gynecology. 2000;183:s1-s22. doi: 10.1067/mob.2000.107928.
- 425 7. Umesawa M, Kobashi G. Epidemiology of hypertensive disorders in pregnancy:
- prevalence, risk factors, predictors and prognosis. *Hypertens Res.* 2017;40:213–
- 427 220. doi: 10.1038/hr.2016.126.
- 428 8. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking:
- 429 systematic review of controlled studies. *BMJ*. 2005;330:565. doi:
- 430 10.1136/bmj.38380.674340.E0.
- 431 9. Garovic VD, Dechend R, Easterling T, Karumanchi SA, McMurtry Baird S,
- 432 Magee LA, Rana S, Vermunt JV, August P. Hypertension in Pregnancy:
- Diagnosis, Blood Pressure Goals, and Pharmacotherapy: A Scientific Statement
- From the American Heart Association. *Hypertension*. 2022;79:e21-e41. doi:
- 435 10.1161/HYP.0000000000000208.

- 436 10. Crump C, Sundquist J, McLaughlin MA, Dolan SM, Govindarajulu U, Sieh W,
- 437 Sundquist K. Adverse pregnancy outcomes and long term risk of ischemic heart
- disease in mothers: national cohort and co-sibling study. *BMJ*.
- 439 2023;380:e072112. doi: 10.1136/bmj-2022-072112.
- 440 11. Rayes B, Ardissino M, Slob EAW, Patel KHK, Girling J, Ng FS. Association of
- 441 Hypertensive Disorders of Pregnancy With Future Cardiovascular Disease.
- 442 *JAMA Netw Open.* 2023;6:e230034. doi: 10.1001/jamanetworkopen.2023.0034.
- 443 12. Ying W, Catov JM, Ouyang P. Hypertensive Disorders of Pregnancy and Future
- 444 Maternal Cardiovascular Risk. *J Am Heart Assoc.* 2018;7:e009382. doi:
- 445 10.1161/JAHA.118.009382.
- 446 13. O'Kelly AC, Michos ED, Shufelt CL, Vermunt JV, Minissian MB, Quesada O,
- Smith GN, Rich-Edwards JW, Garovic VD, El Khoudary SR, et al. Pregnancy
- and Reproductive Risk Factors for Cardiovascular Disease in Women. Circ Res.
- 449 2022;130:652–672. doi: 10.1161/CIRCRESAHA.121.319895.
- 450 14. Skrivankova VW, Richmond RC, Woolf BAR, Yarmolinsky J, Davies NM,
- Swanson SA, VanderWeele TJ, Higgins JPT, Timpson NJ, Dimou N, et al.
- 452 Strengthening the Reporting of Observational Studies in Epidemiology Using
- 453 Mendelian Randomization: The STROBE-MR Statement. *JAMA*.
- 454 2021;326:1614–1621. doi: 10.1001/jama.2021.18236.
- 455 15. Allen N, Sudlow C, Downey P, Peakman T, Danesh J, Elliott P, Gallacher J,
- 456 Green J, Matthews P, Pell J, et al. UK Biobank: Current status and what it
- 457 means for epidemiology. *Health Policy and Technology*. 2012;1:123–126. doi:
- 458 10.1016/j.hlpt.2012.07.003.
- 459 16. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, Downey P, Elliott
- 460 P, Green J, Landray M, et al. UK biobank: an open access resource for
- identifying the causes of a wide range of complex diseases of middle and old
- 462 age. *PLoS Med*. 2015;12:e1001779. doi: 10.1371/journal.pmed.1001779.
- 463 17. Collins R. What makes UK Biobank special? *Lancet*. 2012;379:1173–1174. doi:
- 464 10.1016/S0140-6736(12)60404-8.
- 465 18. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, Motyer A,
- Vukcevic D, Delaneau O, O'Connell J, et al. Genome-wide genetic data on
- 467 ~500,000 UK Biobank participants. 2017. doi: 10.1101/166298.
- 468 19. Honigberg MC, Truong B, Khan RR, Xiao B, Bhatta L, Vy TH, Guerrero RF,
- Schuermans A, Selvaraj MS, Patel AP, et al. Genome-wide meta-analysis

- 470 identifies novel maternal risk variants and enables polygenic prediction of
- 471 preeclampsia and gestational hypertension. 2022. doi:
- 472 10.1101/2022.11.30.22282929.
- 473 20. Kamat MA, Blackshaw JA, Young R, Surendran P, Burgess S, Danesh J,
- Butterworth AS, Staley JR. PhenoScanner V2: an expanded tool for searching
- human genotype-phenotype associations. *Bioinformatics*. 2019;35:4851–4853.
- doi: 10.1093/bioinformatics/btz469.
- 477 21. Privé F, Luu K, Blum MGB, McGrath JJ, Vilhjálmsson BJ. Efficient toolkit
- implementing best practices for principal component analysis of population
- 479 genetic data. *Bioinformatics*. 2020;36:4449–4457. doi:
- 480 10.1093/bioinformatics/btaa520.
- 481 22. Yavorska OO, Burgess S. MendelianRandomization: an R package for
- 482 performing Mendelian randomization analyses using summarized data. Int J
- 483 *Epidemiol.* 2017;46:1734–1739. doi: 10.1093/ije/dyx034.
- 484 23. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal
- pleiotropy in causal relationships inferred from Mendelian randomization
- between complex traits and diseases. *Nat Genet.* 2018;50:693–698. doi:
- 487 10.1038/s41588-018-0099-7.
- 488 24. Grandi SM, Filion KB, Yoon S, Ayele HT, Doyle CM, Hutcheon JA, Smith GN,
- Gore GC, Ray JG, Nerenberg K, et al. Cardiovascular Disease-Related
- 490 Morbidity and Mortality in Women With a History of Pregnancy Complications.
- 491 *Circulation*. 2019;139:1069–1079. doi:
- 492 10.1161/CIRCULATIONAHA.118.036748.
- 493 25. Ardissino M, Slob EAW, Millar O, Reddy RK, Lazzari L, Patel KHK, Ryan D,
- Johnson MR, Gill D, Ng FS. Maternal Hypertension Increases Risk of
- 495 Preeclampsia and Low Fetal Birthweight: Genetic Evidence From a Mendelian
- 496 Randomization Study. *Hypertension*. 2022;79:588–598. doi:
- 497 10.1161/HYPERTENSIONAHA.121.18617.
- 498 26. Malik R, Georgakis MK, Vujkovic M, Damrauer SM, Elliott P, Karhunen V,
- Giontella A, Fava C, Hellwege JN, Shuey MM, et al. Relationship Between Blood
- 500 Pressure and Incident Cardiovascular Disease: Linear and Nonlinear Mendelian
- 501 Randomization Analyses. *Hypertension*. 2021;77:2004–2013. doi:
- 502 10.1161/HYPERTENSIONAHA.120.16534.

- 503 27. Burgess S, Thompson SG. Interpreting findings from Mendelian randomization
- using the MR-Egger method. *Eur J Epidemiol*. 2017;32:377–389. doi:
- 505 10.1007/s10654-017-0255-x.
- 506 28. Bateman BT, Schumacher HC, Bushnell CD, Pile-Spellman J, Simpson LL,
- Sacco RL, Berman MF. Intracerebral hemorrhage in pregnancy: frequency, risk
- factors, and outcome. *Neurology*. 2006;67:424–429. doi:
- 509 10.1212/01.wnl.0000228277.84760.a2.
- 510 29. Hung S-K, Lee M-S, Lin H-Y, Chen L-C, Chuang C-J, Chew C-H, Yu B-H, Yang
- 511 H-J, Hsu F-C, Chiou W-Y. Impact of Hypertensive Disorders of Pregnancy on
- the Risk of Stroke Stratified by Subtypes and Follow-Up Time. *Stroke*.
- 513 2022;53:338–344. doi: 10.1161/STROKEAHA.121.034109.
- 30. Auger N, Fraser WD, Schnitzer M, Leduc L, Healy-Profitós J, Paradis G.
- Recurrent pre-eclampsia and subsequent cardiovascular risk. *Heart*.
- 516 2017;103:235–243. doi: 10.1136/heartjnl-2016-309671.
- 31. Robillard P-Y, Dekker G, Scioscia M. The necessity to specify paternities in all
- obstetrical files in multigravidae. *J Reprod Immunol.* 2022;154:103747. doi:
- 519 10.1016/j.jri.2022.103747.
- 520 32. Peters SAE, Singhateh Y, Mackay D, Huxley RR, Woodward M. Total
- 521 cholesterol as a risk factor for coronary heart disease and stroke in women
- 522 compared with men: A systematic review and meta-analysis. *Atherosclerosis*.
- 523 2016;248:123–131. doi: 10.1016/j.atherosclerosis.2016.03.016.
- 524 33. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood
- 525 AM, Lewington S, Sattar N, Packard CJ, et al. Major lipids, apolipoproteins, and
- 526 risk of vascular disease. *JAMA*. 2009;302:1993–2000. doi:
- 527 10.1001/jama.2009.1619.

528

Figure Legends

529

556

557

lipoprotein; LDL, low-density lipoprotein.

530 Figure 1. Sex-specific Mendelian Randomisation analysis of genetically 531 proxied pre-eclampsia/eclampsia and risk of cardiovascular events. Results are 532 from inverse variance weighted regression. Models were adjusted for age at baseline 533 and the first 16 genetic principal components. Abbreviations: CI, confidence interval; 534 CVD, cardiovascular disease; ICH, intracerebral haemorrhage; MI, myocardial 535 infarction; OR, odds ratio; SAH, subarachnoid haemorrhage. 536 Figure 2. Sex-specific Mendelian Randomisation analysis of genetically 537 proxied gestational hypertension and risk of cardiovascular events. Results are 538 from inverse variance weighted regression. Models were adjusted for age at baseline 539 and the first 16 genetic principal components. Abbreviations: CI, confidence interval; 540 CVD, cardiovascular disease; ICH, intracerebral haemorrhage; MI, myocardial 541 infarction; OR, odds ratio; SAH, subarachnoid haemorrhage. 542 Figure 3. Sex-specific Mendelian Randomisation analysis of genetically 543 proxied pre-eclampsia/eclampsia and cardiovascular risk factors. Results are 544 from inverse variance weighted regression Results are from inverse variance 545 weighted regression. Models were adjusted for age at baseline and the first 16 546 genetic principal components. Abbreviations: ALAT, alanine aminotransferase; 547 aspartate aminotransferase; CI, confidence interval; GGT, gamma 548 glutamyltransferase; HbA1c, glycated haemoglobin; HDL, high-density lipoprotein; 549 LDL, low-density lipoprotein. 550 Figure 4. Sex-specific Mendelian Randomisation analysis of genetically 551 proxied gestational hypertension and cardiovascular risk factors. Results are 552 from inverse variance weighted regression. Models were adjusted for age at baseline 553 and the first 16 genetic principal components. Abbreviations: ALAT, alanine 554 aminotransferase; ASAT, aspartate aminotransferase; CI, confidence interval; GGT, 555 gamma glutamyltransferase; HbA1c, glycated hemoglobin; HDL, high-density

Tables

Table 1. Participant characteristics.

	Overall (n=487,203)		Women (n=264,160)		Men (n=223,043)	
Characteristic	N	Mean ± SD, median [IQR], N (%)	N	Mean ± SD, median [IQR], N (%)	N	Mean ± SD, median [IQR], N (%)
Age, years	487,203	56.5 ± 8.1	264,160	56.4 ± 8.0	223,043	56.7 ± 8.2
SBP, mmHg	460,029	137.8 ± 18.7	249,189	135.2 ± 19.2	210,840	140.9 ± 17.5
DBP, mmHg	460,034	82.2 ± 10.1	249,192	80.7 ± 10.0	210,842	84.1 ± 10.0
Hypertension	474,896	224,331 (47.2%)	264,054	117,037 (44.3%)	210,842	107,294 (50.9%)
Age at hypertension diagnosis, years	117,548	50.6 ± 9.9	54,552	50.0 ± 10.8	62,996	51.2 ± 9.1
Body mass index, kg/m2	485,231	27.4 ± 4.8	263,213	27.1 ± 5.2	222,018	27.8 ± 4.2
Smoking status	484,701		262,851		221,850	
Never		265,322 (54.7%)		156,643 (59.6%)		108,679 (49.0%)
Ex		168,194 (34.7%)		82,760 (31.5%)		85,434 (38.5%)
Current		51,185 (10.6%)		23,448 (8.9%)		27,737 (12.5%)
Total cholesterol, mmol/L	464,313	5.7 ± 1.1	251,599	5.9 ± 1.1	212,714	5.5 ± 1.1
HDL cholesterol, mmol/L	424,993	1.4 ± 0.4	228,604	1.6 ± 0.4	196,389	1.3 ± 0.3
Triglycerides, mmol/L	463,945	1.5 [1.0, 2.1]	251,460	1.3 [1.0, 1.9]	212,485	1.7 [1.2, 2.4]
LDL cholesterol, mmol/L	463,446	3.6 ± 0.9	251,188	3.6 ± 0.9	212,258	3.5 ± 0.9
Lipoprotein(a), nmol/L	371,400	21.1 [9.6, 61.9]	201,844	22.2 [9.9, 62.0]	169,556	19.8 [9.2, 61.8]
Apolipoprotein A1, g/L	422,655	1.5 ± 0.3	226,557	1.6 ± 0.3	196,098	1.4 ± 0.2
Apolipoprotein B, g/L	461,972	1.0 ± 0.2	250,732	1.0 ± 0.2	211,240	1.0 ± 0.2
HbA1c, mmol/mol	462,868	36.1 ± 6.8	250,932	35.8 ± 6.0	211,936	36.5 ± 7.6
Creatinine, µmol/L	464,085	70.4 [61.4, 80.9]	251,489	63.1 [57.0, 70.0]	212,596	80.0 [72.5, 88.4]
Albumin, g/L	425,194	45.2 ± 2.6	228,687	44.9 ± 2.6	196,507	45.5 ± 2.6
ALAT, U/L	464,133	20.1 [15.4, 27.4]	251,592	17.5 [13.9, 22.9]	212,541	23.9 [18.4, 32.0]
ASAT, U/L	462,594	24.4 [21.0, 28.8]	250,727	23.0 [20.0, 26.8]	211,867	26.2 [22.6, 31.0]
Gamma-GT, U/L	464,074	26.3 [18.5, 41.0]	251,496	21.4 [16.1, 31.9]	212,578	33.1 [23.7, 50.3]
C-reactive protein, mg/L	463,305	1.3 [0.7, 2.8]	251,162	1.4 [0.6, 3.0]	212,143	1.3 [0.7, 2.5]

Abbreviations: ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase; DBP, diastolic blood pressure; ALAT, alanine aminotransferase; ASAT, aspartate aminotransferase;; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; SBP, systolic blood pressure; SD, standard deviation.







